Investment Summary

SHS Invests In Affimed Therapeutics AG

On May 1, 2005, private equity firm SHS invested in life science company Affimed Therapeutics AG

Investment Highlights
  • This is SHS’s 3rd transaction in the Life Science sector.
  • This is SHS’s 4th transaction in Germany.

Investment Summary

Date 2005-05-01
Target Affimed Therapeutics AG
Sector Life Science
Investor(s) SHS
Deal Type Growth Capital

Target

Affimed Therapeutics AG

Heidelberg, Germany
website
Affimed Therapeutics AG develops Human antibody therapeutics.

Search 177,960 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor
DESCRIPTION

SHS is a private equity firm focused on the healthcare sector. Specific areas of interest include life science, medical technology, diagnostics, applied technologies, digital health, and industrial biotechnology. The Firm will consider opportunities at all company stages and looks to commit up to €30 million in businesses valued up to €100 million. Target geographies include Germany, Austria, Switzerland, Scandinavia, and Benelux. SHS was established in 1993 and is headquartered in Tubingen, Germany.


DEAL STATS #
Overall 4 of 26
Sector (Life Science) 3 of 8
Type (Growth Capital) 3 of 15
Country (Germany) 4 of 17
Year (2005) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2003-06-12 ProBioGen AG

Berlin, Germany

ProBioGen AG optimization of mammalian cell lines for production and manufacturing of recombinant proteins.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2006-03-01 Acino

Zurich, Czech Republic

Acino is a pharmaceutical company focused on developing, manufacturing and marketing well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino was founded in 1836 and is based in Zurich, Czech Republic.

Buy -